Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Anti-glomerular basement membrane disease accompanied by systemic lupus erythematosus presenting central nervous system involvement.

Sugawara H, Takizawa H, Shimamura Y, Moniwa N, Hasegawa K, Ogawa Y.

CEN Case Rep. 2017 May;6(1):1-4. doi: 10.1007/s13730-016-0233-2. Epub 2016 Aug 27.

2.

Modelling clinical systemic lupus erythematosus: similarities, differences and success stories.

Celhar T, Fairhurst AM.

Rheumatology (Oxford). 2017 Apr 1;56(suppl_1):i88-i99. doi: 10.1093/rheumatology/kew400. Review.

3.

A systems approach to renal inflammation in SLE.

Berthier CC, Kretzler M, Davidson A.

Clin Immunol. 2016 Aug 14. pii: S1521-6616(16)30292-3. doi: 10.1016/j.clim.2016.08.015. [Epub ahead of print]

PMID:
27534926
4.

Blockade of CD354 (TREM-1) Ameliorates Anti-GBM-Induced Nephritis.

Du Y, Wu T, Zhou XJ, Davis LS, Mohan C.

Inflammation. 2016 Jun;39(3):1169-76. doi: 10.1007/s10753-016-0351-1.

5.

Involvement of Kallikrein-Related Peptidases in Normal and Pathologic Processes.

Stefanini AC, da Cunha BR, Henrique T, Tajara EH.

Dis Markers. 2015;2015:946572. doi: 10.1155/2015/946572. Epub 2015 Dec 9. Review.

6.

What is damaging the kidney in lupus nephritis?

Davidson A.

Nat Rev Rheumatol. 2016 Mar;12(3):143-53. doi: 10.1038/nrrheum.2015.159. Epub 2015 Nov 19. Review.

7.

Genetics of Lupus Nephritis: Clinical Implications.

Munroe ME, James JA.

Semin Nephrol. 2015 Sep;35(5):396-409. doi: 10.1016/j.semnephrol.2015.08.002. Review.

8.
9.
10.

Kallikrein-kinin in stem cell therapy.

Chao J, Bledsoe G, Chao L.

World J Stem Cells. 2014 Sep 26;6(4):448-57. doi: 10.4252/wjsc.v6.i4.448. Review.

11.

Forward genetic approaches for elucidation of novel regulators of Lyme arthritis severity.

Bramwell KK, Teuscher C, Weis JJ.

Front Cell Infect Microbiol. 2014 Jun 5;4:76. doi: 10.3389/fcimb.2014.00076. eCollection 2014. Review.

12.
13.

Identical twins:one with anti-glomerular basement membrane glomerulonephritis,the other with systemic lupus erythematosus.

Liu X, Wu Y, Yang Y, Wang J, Tao Y, Fu P, Hu Z.

BMC Nephrol. 2013 Dec 20;14:277. doi: 10.1186/1471-2369-14-277.

14.
15.

Kallikrein transduced mesenchymal stem cells protect against anti-GBM disease and lupus nephritis by ameliorating inflammation and oxidative stress.

Li Y, Raman I, Du Y, Yan M, Min S, Yang J, Fang X, Li W, Lu J, Zhou XJ, Mohan C, Li QZ.

PLoS One. 2013 Jul 23;8(7):e67790. doi: 10.1371/journal.pone.0067790. Print 2013.

16.

Genetic contribution and associated pathophysiology in end-stage renal disease.

Agrawal S, Agarwal S, Naik S.

Appl Clin Genet. 2010 Aug 5;3:65-84. Print 2010.

17.

Biomarker profiling for lupus nephritis.

Li Y, Fang X, Li QZ.

Genomics Proteomics Bioinformatics. 2013 Jun;11(3):158-65. doi: 10.1016/j.gpb.2013.05.003. Epub 2013 Jun 1. Review.

18.

From the Large Scale Expression Analysis of Lupus Nephritis to Targeted Molecular Medicine.

Berthier CC, Kretzler M, Davidson A.

J Data Mining Genomics Proteomics. 2012 Mar 27;3(3). pii: 1000123.

19.

Treatment targets in systemic lupus erythematosus: biology and clinical perspective.

Marian V, Anolik JH.

Arthritis Res Ther. 2012;14 Suppl 4:S3. doi: 10.1186/ar3917. Epub 2012 Nov 30. Review.

20.

Taming lupus-a new understanding of pathogenesis is leading to clinical advances.

Liu Z, Davidson A.

Nat Med. 2012 Jun 6;18(6):871-82. doi: 10.1038/nm.2752. Review.

Supplemental Content

Support Center